You can buy or sell CBMG and other stocks, options, ETFs, and crypto commission-free!
Cellular Biomedicine Group, Inc. Common Stock, also called Cellular Biomedicine Group, is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Read More Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. The company was founded in 2009 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
PR NewswireMar 20
Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock
NEW YORK, March 20, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CBMG also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the sha...
Stock Price, News, & Analysis for Cellular Biomedicine Group
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of...
Markets InsiderFeb 27
Cellular Biomedicine Group to Present at 8th Annual SVB Leerink Global Healthcare Conference
SHANGHAI and NEW YORK, Feb. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Derrick Li, Head of Strategy and Investor Relations, will present a Company update at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Friday, March 1st at 11:30 AM EST. About Cellular Biomedicine Group Cel...
Expected May 6, Pre-Market